Diane Stadler

Dr. Diane Stadler


Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
AHAndrea M. Haqq
Andrea M. Haqq
IFI. Sadaf Farooqi
I. Sadaf Farooqi
SOStephen O’rAhilly
Stephen O’rAhilly
DSDiane Stadler
Diane Stadler
RRRon G. Rosenfeld
Ron G. Rosenfeld
JPJonathan Q. Purnell
Jonathan Q. Purnell
Ghrelin, an endogenous ligand of the GH secretagogue receptor, stimulates appetite and causes obesity in animal models and in humans when given in pharmacologic doses. Prader-Willi Syndrome (PWS) is a genetic obesity syndrome characterized by GH deficiency and the onset of a voracious appetite and obesity in childhood. We, therefore, hypothesized that ghrelin levels may play a role in the expression of obesity in this syndrome. We measured fasting serum ghrelin levels in 13 PWS children with an average age of 9.5 yr (range, 5-15) and body mass index (BMI) of 31.3 kg/m2 (range, 22-46). The PWS group was compared with 4 control groups: 20 normal weight controls matched for age and sex, 17 obese children (OC), and 14 children with melanocortin-4 receptor mutations (MC4) matched for age, sex, and BMI, and a group of 3 children with leptin deficiency (OB). In non-PWS subjects, ghrelin levels were inversely correlated with age (r = 0.36, P = 0.007), insulin (r = 0.55, P < 0.001), and BMI (r = 0.62, P < 0.001), but not leptin. In children with PWS, fasting ghrelin concentrations were not significantly different compared with normal weight controls (mean +/- SD; 429 +/- 374 vs. 270 +/- 102 pmol/liter; P = 0.14). However, children with PWS did demonstrate higher fasting ghrelin concentrations (3- to 4-fold elevation) compared with all obese groups (OC, MC4, OB) (mean +/- SD; 429 +/- 374 vs. 139 +/- 70 pmol/liter; P < 0.001). In conclusion, ghrelin levels in children with PWS are significantly elevated (3- to 4-fold) compared with BMI-matched obese controls (OC, MC4, OB). Elevation of serum ghrelin levels to the degree documented in this study may play a role as an orexigenic factor driving the insatiable appetite and obesity found in PWS.

1 November 2007 in Journal of the American Dietetic Association
Verified
Journal Article
Closed access
STSherry Tanumihardjo
Sherry Tanumihardjo
CACheryl Anderson
Cheryl Anderson
MKMartha Kaufer-Horwitz
Martha Kaufer-Horwitz
LBLars Bode
Lars Bode
NENancy J. Emenaker
Nancy J. Emenaker
DSDiane Stadler
Diane Stadler

1 May 2003 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
AHAndrea M. Haqq
Andrea M. Haqq
DSDiane Stadler
Diane Stadler
RJRussell H. Jackson
Russell H. Jackson
RRRon G. Rosenfeld
Ron G. Rosenfeld
JPJonathan Q. Purnell
Jonathan Q. Purnell
SLStephen H. LaFranchi
Stephen H. LaFranchi
The objective of this study was to investigate the effects of GH administration on pulmonary function, sleep, behavior, cognition, linear growth velocity, body composition, and resting energy expenditure (REE) in children with Prader-Willi syndrome. The study used a 12-month, balanced, randomized, double-blind, placebo-controlled, cross-over experimental design. Twelve subjects were randomized to GH (0.043 mg/kg x d) or placebo intervention for 6 months and then crossed over to the alternate intervention for 6 months. Differences in outcome variables were determined by paired t tests. Peak flow rate, percentage vital capacity, and forced expiratory flow rate improved and number of hypopnea and apnea events and duration of apnea events trended toward improvement after GH intervention. The only difference in cognition or behavior was an increase in hyperactivity scale on the Behavior Assessment System for Children after GH intervention. Linear growth velocity, REE, and lean mass were higher (67%, 19%, and 7.6%, respectively), and fat mass and percentage body fat were lower (10.3% and 8.1%, respectively) after GH intervention. GH administration did not change mean fasting ghrelin concentration. GH intervention improved body composition and REE and may contribute to better sleep quality and pulmonary function. GH administration did not impact fasting ghrelin concentration.

1 August 2003 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
AHAndrea M. Haqq
Andrea M. Haqq
DSDiane Stadler
Diane Stadler
RRRon G. Rosenfeld
Ron G. Rosenfeld
KPKatherine L. Pratt
Katherine L. Pratt
DWDavid S. Weigle
David S. Weigle
JPJonathan Q. Purnell
Jonathan Q. Purnell
Prader-Willi syndrome (PWS) is characterized by severe obesity, hyperphagia, hypogonadism, and GH deficiency. Unlike individuals with common obesity, who have low fasting-plasma ghrelin concentrations, those with PWS have high fasting-ghrelin concentrations that might contribute to their hyperphagia. Treatment with octreotide, a somatostatin agonist, decreases ghrelin concentrations in healthy and acromegalic adults and induces weight loss in children with hypothalamic obesity. This pilot study was performed to determine whether octreotide administration (5 microg/kg.d) for 5-7 d lowers ghrelin concentrations and affects body composition, resting energy expenditure, and GH markers in children with PWS. Octreotide treatment decreased mean fasting plasma ghrelin concentration by 67% (P < 0.05). Meal-related ghrelin suppression (-35%; P < 0.001) was still present after intervention but was blunted (-11%; P = 0.19). Body weight, body composition, leptin, insulin, resting energy expenditure, and GH parameters did not change. However, one subject's parent noted fewer tantrums over denial of food during octreotide intervention. In conclusion, short-term octreotide treatment markedly decreased fasting ghrelin concentrations in children with PWS but did not fully ablate the normal meal-related suppression of ghrelin. Further investigation is warranted to determine whether long-term octreotide treatment causes sustained ghrelin suppression, changes eating behavior, and induces weight loss in this population.

1 January 2011 in International Journal of Behavioral Nutrition and Physical Activity
Verified
Journal Article
Open access
PDF file
ASAnna Maria Siega-Riz
Anna Maria Siega-Riz
LGLaurie El Ghormli
Laurie El Ghormli
CMConnie Mobley
Connie Mobley
BGBonnie Gillis
Bonnie Gillis
DSDiane Stadler
Diane Stadler
HGHealthy Study Group
Healthy Study Group
The HEALTHY study was designed to respond to the alarming trends in increasing rates of overweight, obesity, and type 2 diabetes mellitus in youth. The objective of this analysis was to examine the effects of the HEALTHY study on student self-reported dietary intakes (energy, macronutrients and grams consumed of selected food groups).

20 September 2011 in BMC Public Health
Verified
Journal Article
Open access
PDF file
TGthe HEALTHY study group
the HEALTHY study group
LDLynn L DeBar
Lynn L DeBar
MSMargaret Schneider
Margaret Schneider
KDKimberly L Drews
Kimberly L Drews
EFEileen G Ford
Eileen G Ford
EVElizabeth M Venditti
Elizabeth M Venditti
As concern about youth obesity continues to mount, there is increasing consideration of widespread policy changes to support improved nutritional and enhanced physical activity offerings in schools. A critical element in the success of such programs may be to involve students as spokespeople for the program. Making such a public commitment to healthy lifestyle program targets (improved nutrition and enhanced physical activity) may potentiate healthy behavior changes among such students and provide a model for their peers. This paper examines whether student's "public commitment"--voluntary participation as a peer communicator or in student-generated media opportunities--in a school-based intervention to prevent diabetes and reduce obesity predicted improved study outcomes including reduced obesity and improved health behaviors.